Regulation
Artera hits US first with pathology-based breast cancer risk tool’s clearance
ArteraAI received US regulatory clearance for ArteraAI Breast, a pathology-based software tool that stratifies breast cancer patients into risk groups to inform treatment decisions. The clearance marks the first such FDA approval for this class of diagnostic software in the US market.
The source
This brief is a MedIndexer summary of reporting by Medical Device Network. To read the full story, head to the source.
Read the full story at Medical Device Network